TY - JOUR
T1 - Positron Emission Tomography Imaging in Vasculitis
AU - van der Geest, Kornelis S M
AU - Slijkhuis, Berend G C
AU - Tomelleri, Alessandro
AU - Gheysens, Olivier
AU - Jiemy, William F
AU - Piccolo, Costanza
AU - Nienhuis, Pieter
AU - Sandovici, Maria
AU - Brouwer, Elisabeth
AU - Glaudemans, Andor W J M
AU - Mulder, Douwe J
AU - Slart, Riemer H J A
N1 - Copyright © 2025 Elsevier Inc. All rights reserved.
PY - 2025/7
Y1 - 2025/7
N2 - Systemic vasculitides comprise a group of autoimmune diseases affecting blood vessels. [18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) plays an important role in the diagnosis and therapeutic monitoring of vasculitides affecting large-sized and medium-sized vessels. FDG-PET/CT also provides complementary information to other vascular imaging tools. The resolution and sensitivity of newer generation scanners continues to increase, hereby improving the ability of FDG-PET/CT to accurately assess the full disease extent in patients with vasculitis. Novel tracers targeting specific immune cells will allow for more detailed detection of vascular infiltrates.
AB - Systemic vasculitides comprise a group of autoimmune diseases affecting blood vessels. [18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) plays an important role in the diagnosis and therapeutic monitoring of vasculitides affecting large-sized and medium-sized vessels. FDG-PET/CT also provides complementary information to other vascular imaging tools. The resolution and sensitivity of newer generation scanners continues to increase, hereby improving the ability of FDG-PET/CT to accurately assess the full disease extent in patients with vasculitis. Novel tracers targeting specific immune cells will allow for more detailed detection of vascular infiltrates.
KW - Humans
KW - Vasculitis/diagnostic imaging
KW - Positron Emission Tomography Computed Tomography/methods
KW - Fluorodeoxyglucose F18
KW - Positron-Emission Tomography/methods
KW - Radiopharmaceuticals
U2 - 10.1016/j.hfc.2025.01.007
DO - 10.1016/j.hfc.2025.01.007
M3 - Review article
C2 - 40506158
SN - 1551-7136
VL - 21
SP - 461
EP - 475
JO - Heart failure clinics
JF - Heart failure clinics
IS - 3
ER -